这页已由机器翻译。其他页面可能仍然显示为英文。 View in English

澳大利亚和新西兰局部性前列腺癌的治疗变化:注册研究

Karen Chiam ¹, Albert Bang ¹, Visalini Nair-Shalliker ^1,2

¹The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.
²Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
³Sydney School of Public Health, Faculty of Health and Medicine, The University of Sydney, Sydney, New South Wales, Australia.
⁴Speciality of Surgery, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
⁵Department of Urology, Westmead Hospital, Westmead, New South Wales, Australia.
⁶Department of Urology, Eastern Health, Box Hill, Victoria, Australia.
⁷Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia.
⁸Department of Urology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
⁹Australian Prostate Cancer Research Centre, Queensland University of Technology, Brisbane, Queensland, Australia.
¹⁰Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
¹¹Department of Radiation Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
¹²Genesis Cancer Care, Sydney, New South Wales, Australia.
¹³Department of Urology, Blacktown and Mount Druitt Hospitals, Blacktown, New South Wales, Australia.
¹⁴College of Health and Medicine, Australian National University, Canberra, ACT, Australia.
¹⁵College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
¹⁶Department of Urology, SA Health, Flinders Medical Centre, Bedford Park, South Australia, Australia.
¹⁷South Australian Prostate Cancer Clinical Outcomes Collaborative, Adelaide, South Australia, Australia.
¹⁸Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
¹⁹University of South Australia, Adelaide, South Australia, Australia.
²⁰Urology Unit, Flinders Medical Centre, Bedford Park, South Australia, Australia.
²¹School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

⁰The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.

Bju International +

|

2025年八月22日

在PubMed上查看摘要

概括

社会经济地位和医院提供者影响局部前列腺癌治疗决策. 这些因素影响了从根本性前列腺切除与其他疗法之间的选择, 不管患者的年龄或疾病风险如何.

科学领域

癌症学
公共卫生
医疗服务研究

背景情况

局部性前列腺癌的治疗有很大的差异.
了解影响治疗的因素对于公平护理至关重要.

研究的目的

描述局部前列腺癌的治疗模式.
使用前列腺癌结局注册 - 澳大利亚和新西兰 (PCOR- ANZ) 数据库来确定与治疗吸收相关的因素.

主要方法

分析了2015年至2018年期间在澳大利亚和新西兰诊断的36,504名患者.
多项逻辑回归以比较治疗方法 (没有活性治疗,放射治疗,抗雄激素治疗,ADT+RT组合) 与激进前列腺切除术.

主要成果

中级风险疾病 (49. 2%) 和急性前列腺切除术 (40. 3%) 是最常见的.
较低的社会经济地位和地区性医院诊断与非激进性前列腺切除治疗的可能性更高有关.
最低的SES组没有积极治疗,放射治疗和抗雄激素治疗的几率明显更高.

结论

社会经济地位和医院提供者是局部前列腺癌治疗选择的重要独立因素.
这些发现突显了前列腺癌治疗的潜在差异.

关键词:

护理模式人口健康前列腺癌登记处处理方式